In this interview with Dr. Stuart Silverman, we discuss his WCO-IOF-ESCEO 2025 presentation on the clinical utility of bone turnover markers (BTMs) in osteoporosis care. BTMs such as s-CTX and s-PINP, standardized by the IOF-IFCC, provide insights into bone remodelling, support treatment monitoring, guide therapy adjustments, and help personalize drug holidays, though they complement rather than replace traditional diagnostic tools.

Dr. Vinod Ravindran (Centre for Rheumatology, Calicut, Kerala, India) shares his highlights from RheumaPreg 2025, held in Vienna. The conference covered the full spectrum of pregnancy management in autoimmune rheumatic diseases. Here, he reflects on key insights from expert-led sessions on fertility, immunosuppression, lupus care, and postpartum outcomes.

In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.

Osteoarthritis is increasingly recognised as a heterogeneous disease with diverse clinical phenotypes and molecular endotypes. In this expert Q&A, Professor Ali Mobasheri discusses how precision medicine—through clinical phenotyping and molecular endotyping—can guide targeted therapies, accelerate the development of disease-modifying treatments, and transform OA management into a personalised, proactive approach that improves patient outcomes.

At the 2025 WCO-IOF-ESCEO congress, Professor Philip Conaghan presented the safety and efficacy findings from the phase 2 study of LEVI-04 for the treatment of adults with knee osteoarthritis. LEVI-04 is a first-in-class, NT-3 inhibitor, which works by targeting the inflammatory pathways involved in joint degeneration and selectively inhibiting pro-inflammatory cytokines.

Epinephrine is the first-line treatment for severe allergic reactions, including anaphylaxis, where prompt intervention is crucial. Epinephrine sublingual film, a novel prodrug of epinephrine, is being developed to treat Type 1 allergic reactions, such as anaphylaxis. In the OASIS study, epinephrine sublingual film demonstrated equal or superior pharmacokinetics compared to intramuscular epinephrine in adult patients with oral allergy syndrome. The film led to rapid symptom resolution, with a median recovery time of 12 minutes. Additionally, stability tests showed that the film remained effective under extreme temperatures and real-world conditions, ensuring its reliability as an emergency treatment for anaphylaxis.